Published in FEBS Lett on February 27, 2003
Investigating diversity in human plasma proteins. Proc Natl Acad Sci U S A (2005) 1.88
Glycosylation status of vitamin D binding protein in cancer patients. Protein Sci (2009) 1.03
Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes. Proteomics Clin Appl (2013) 0.96
Injury severity and serum amyloid A correlate with plasma oxidation-reduction potential in multi-trauma patients: a retrospective analysis. Scand J Trauma Resusc Emerg Med (2009) 0.93
Population studies of intact vitamin D binding protein by affinity capture ESI-TOF-MS. J Biomol Tech (2008) 0.86
High-density lipoprotein proteome dynamics in human endotoxemia. Proteome Sci (2011) 0.85
Mass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms. Proteomes (2016) 0.85
Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer (2010) 0.84
Serum amyloid a truncations in type 2 diabetes mellitus. PLoS One (2015) 0.84
A qualitative and quantitative proteomic study of human microdialysate and the cutaneous response to injury. AAPS J (2011) 0.82
Biochemical and functional characterization of charge-defined subfractions of high-density lipoprotein from normal adults. Anal Chem (2013) 0.76
A Novel Truncated Form of Serum Amyloid A in Kawasaki Disease. PLoS One (2016) 0.75
Mass spectrometric immunoassays for discovery, screening and quantification of clinically relevant proteoforms. Bioanalysis (2016) 0.75
Development of quantitative mass spectrometric immunoassay for serum amyloid A. Biomarkers (2016) 0.75
Investigating diversity in human plasma proteins. Proc Natl Acad Sci U S A (2005) 1.88
Surface plasmon resonance imaging measurements of antibody arrays for the multiplexed detection of low molecular weight protein biomarkers. Anal Chem (2006) 1.56
Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail (2008) 1.37
Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin Chem (2009) 1.28
Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins. J Lipid Res (2002) 1.16
Population proteomics: the concept, attributes, and potential for cancer biomarker research. Mol Cell Proteomics (2006) 1.12
Investigation of human protein variants and their frequency in the general population. Mol Cell Proteomics (2007) 1.10
High-throughput protein characterization using mass spectrometric immunoassay. Anal Biochem (2002) 1.08
RNA-protein binding interface in the telomerase ribonucleoprotein. Proc Natl Acad Sci U S A (2011) 1.06
High-throughput comprehensive analysis of human plasma proteins: a step toward population proteomics. Anal Chem (2004) 1.06
Transduction of biologically active motifs of the small heat shock-related protein HSP20 leads to relaxation of vascular smooth muscle. FASEB J (2003) 1.05
Glycosylation status of vitamin D binding protein in cancer patients. Protein Sci (2009) 1.03
Quantitative multiplexed C-reactive protein mass spectrometric immunoassay. J Proteome Res (2006) 1.02
Quantitative mass spectrometric immunoassay of insulin like growth factor 1. J Proteome Res (2004) 1.02
Comparative phenotypic analyses of human plasma and urinary retinol binding protein using mass spectrometric immunoassay. Biochem Biophys Res Commun (2002) 1.01
Full-length characterization of proteins in human populations. Clin Chem (2009) 1.01
Proteomic characterization of novel serum amyloid P component variants from human plasma and urine. Proteomics (2004) 0.97
Population studies of Vitamin D Binding Protein microheterogeneity by mass spectrometry lead to characterization of its genotype-dependent O-glycosylation patterns. J Proteome Res (2008) 0.96
Multiplexed mass spectrometric immunoassay in biomarker research: a novel approach to the determination of a myocardial infarct. J Proteome Res (2006) 0.95
Mass spectrometric immunoassay for quantitative determination of protein biomarker isoforms. J Proteome Res (2010) 0.95
Comparative urine protein phenotyping using mass spectrometric immunoassay. J Proteome Res (2003) 0.94
Detection of Staphylococcal enterotoxin B via biomolecular interaction analysis mass spectrometry. Appl Environ Microbiol (2003) 0.93
Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies. Proteomics Clin Appl (2011) 0.92
Detection of bound and free IGF-1 and IGF-2 in human plasma via biomolecular interaction analysis mass spectrometry. FEBS Lett (2003) 0.90
Surface plasmon resonance mass spectrometry: recent progress and outlooks. Trends Biotechnol (2003) 0.89
Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum. Clin Biochem (2013) 0.89
C-peptide microheterogeneity in type 2 diabetes populations. Proteomics Clin Appl (2009) 0.87
Quantitative mass spectrometry evaluation of human retinol binding protein 4 and related variants. PLoS One (2011) 0.87
Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1. PLoS One (2013) 0.87
Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants. Proteomics (2011) 0.87
Development of recombinant-based mass spectrometric immunoassay with application to resistin expression profiling. Anal Chem (2006) 0.86
Targeted quantitative mass spectrometric immunoassay for human protein variants. Proteome Sci (2011) 0.86
Population studies of intact vitamin D binding protein by affinity capture ESI-TOF-MS. J Biomol Tech (2008) 0.86
Building multidimensional biomarker views of type 2 diabetes on the basis of protein microheterogeneity. Clin Chem (2011) 0.86
High-throughput analysis of hemoglobin from neonates using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem (2002) 0.85
Delineating protein-protein interactions via biomolecular interaction analysis-mass spectrometry. J Mol Recognit (2003) 0.85
High-throughput affinity mass spectrometry. Methods Mol Biol (2006) 0.84
Intrapersonal and populational heterogeneity of the chemokine RANTES. Clin Chem (2010) 0.84
High-throughput MS-based protein phenotyping: application to haptoglobin. Proteomics (2005) 0.83
Surface plasmon resonance mass spectrometry for protein analysis. Methods Mol Biol (2006) 0.81
Surface plasmon resonance-enabled mass spectrometry arrays. Electrophoresis (2006) 0.80
Design and use of multi-affinity surfaces in biomolecular interaction analysis-mass spectrometry (BIA/MS): a step toward the design of SPR/MS arrays. J Mol Recognit (2003) 0.79
Multiplexed DNA sequencing-by-synthesis. Anal Biochem (2005) 0.79
Mass spectrometry of nicotinic acetylcholine receptors and associated proteins as models for complex transmembrane proteins. Anal Biochem (2002) 0.78
Examining serum amyloid P component microheterogeneity using capillary isoelectric focusing and MALDI-MS. Proteomics (2010) 0.77
Volumetric mass spectrometry protein arrays. Methods Mol Biol (2007) 0.76
Metal ligand affinity pipettes and bioreactive alkaline phosphatase probes: tools for characterization of phosphorylated proteins and peptides. Mol Cell Proteomics (2004) 0.75
MS-based phenotypic characterization of a human blood protein from urinary waste products. Proteomics Clin Appl (2008) 0.75
Dependence of the ejection velocities of laser-ablated ions on the laser wavelength and fluence. Eur J Mass Spectrom (Chichester, Eng) (2009) 0.75
Design of buffer exchange surfaces and sensor chips for biosensor chip mass spectrometry. Proteomics (2002) 0.75